4D Molecular Therapeutics(FDMT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights • Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study population, affirming favorable safety profile and robust clinical activity • Strengthened senior leadership team and announced formation of a world class Ophthal ...